-
Hedge Fund Manager On WWE: Giving The Service Away For Free Probably Won't Help Earnings
Wednesday, January 28, 2015 - 3:22pm | 411Read More...World Wrestling Entertainment, Inc. (NYSE: WWE) has been making headlines consistently over the past few days. On Monday, Macquarie upgraded the stock after WrestleMania kicked off. On Tuesday, shares were up 20 percent on strong network subscriber numbers. On Wednesday, Lemelson...
-
Hedge Fund Manager Expects 70-75 Million Apple iPhones Sold In FQ1
Tuesday, January 27, 2015 - 2:03pm | 152Read More...When asked about earnings expectations for Apple Inc. (NASDAQ: AAPL), Lemelson Capital Management Chief Investment Officer Rev. Emmanuel Lemelson told Benzinga he expects iPhone sales to be between 70-75 million in the first fiscal quarter. “If these numbers are not reached, it will only...
-
Why This Hedge Fund Manager Thinks Apple Watch Doesn't Need To Succeed In 2015
Monday, January 26, 2015 - 10:25am | 213Read More...In an interview on Benzinga's #PreMarket Prep, Rev. Emmanuel Lemelson from Lemelson Capital Management discussed the importance of the impact on the Apple Watch for 2015, noting that it doesn't necessarily have to succeed immediately to ultimately be a success. Some of Rev. Lemelson...
-
Hedge Fund Manager On Herbalife: 'Bill Ackman Has Been Right All Along'
Thursday, January 8, 2015 - 3:38pm | 188Read More...Speaking to Benzinga, Hedge Fund Manager and Lemelson Capital Management Founder Rev. Emmanuel Lemelson said that he thinks Pershing Square Capital Management CEO Bill Ackman is right about Herbalife Ltd. (NYSE: HLF). “It’s very, very clearly a pyramid scheme,” he said....
-
Why This Hedge Fund Manager Sees Apple At $150
Tuesday, December 30, 2014 - 8:47am | 447Read More...Large companies are usually run better and have superior management, according to hedge fund manager Rev. Emmanuel Lemelson. He said that’s especially true for one big name in his portfolio: Apple Inc. (NASDAQ: AAPL). Lemelson is the Chief Investment Officer of Lemelson Capital...
-
Hedge Fund Guru Emmanuel Lemelson Explains How To Balance Investments And Morality In Ferguson, MO
Wednesday, November 5, 2014 - 2:45pm | 800Read More...Protests and civil disorder began in the town of Ferguson, Missouri after the fatal shooting of Michael Brown on August 9. The media offered what seemed like 24-hour live coverage touching on hot topics including racism, gun control, militarization of police and appropriate use of force....
-
Why WWE Network Subscriptions Might Not Be A Big Deal
Wednesday, October 29, 2014 - 1:53pm | 930Read More...World Wrestling Entertainment, Inc. (NYSE: WWE) is scheduled to report its third quarter results on October 30 before market open. The company is expected to lose $0.17 per share on revenue of $133.2 million, according to consensus analyst estimates. WWE reported its second quarter results on...
-
Lemelson Capital Management Announces Stake In Geospace Technologies
Tuesday, October 21, 2014 - 10:36am | 249Read More...Lemelson Capital Management announced on Monday it has acquired a 2 percent stake in Geospace Technologies Corp (NASDAQ: GEOS). Lemelson Capital Management made headlines recently when BarclayHedge, a global leader in fund performance ranking assessment, ranked Lemelson Capital's Amvona...
-
Why Lemelson Capital Is Short On Ligand Pharmaceuticals
Friday, October 17, 2014 - 3:52pm | 447Read More...Rev. Emmanuel Lemelson is the chief investment officer of Lemelson Capital Management, an investment firm that is short in Ligand Pharmaceuticals Inc. (NASDAQ: LGND). Lemelson recently joined Benzinga’s #PreMarket Prep to talk about why he thinks anyone who is considering investing in...
-
Shares Of Ligand Follow Parabolic Curve Amid Responses Surrounding Promacta's Phase III Trial
Tuesday, June 17, 2014 - 12:26pm | 550Read More...Shares of Ligand Pharmaceuticals (NASDAQ: LGND) are down again following the results of the Phase III trial of Promacta. GSK Releases Promacta Phase III Results In a press release from June 13, GlaxoSmithKline announced the results from the “Phase III PETIT2 study evaluating the efficacy of...
